BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36275712)

  • 1. Reducing farnesyl diphosphate synthase levels activates Vγ9Vδ2 T cells and improves tumor suppression in murine xenograft cancer models.
    Liou ML; Lahusen T; Li H; Xiao L; Pauza CD
    Front Immunol; 2022; 13():1012051. PubMed ID: 36275712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
    Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
    Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
    Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
    Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells.
    Li J; Herold MJ; Kimmel B; Müller I; Rincon-Orozco B; Kunzmann V; Herrmann T
    J Immunol; 2009 Jun; 182(12):8118-24. PubMed ID: 19494338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma.
    Wang Y; Ji N; Zhang Y; Chu J; Pan C; Zhang P; Ma W; Zhang X; Xi JJ; Chen M; Zhang Y; Zhang L; Sun T
    J Transl Med; 2023 Sep; 21(1):672. PubMed ID: 37770968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.
    Sawaisorn P; Gaballa A; Saimuang K; Leepiyasakulchai C; Lertjuthaporn S; Hongeng S; Uhlin M; Jangpatarapongsa K
    Sci Rep; 2024 Jan; 14(1):1291. PubMed ID: 38221530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.
    Riganti C; Castella B; Massaia M
    Front Immunol; 2018; 9():1246. PubMed ID: 29937767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
    Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
    Front Immunol; 2020; 11():1405. PubMed ID: 32793196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-18 activates Vγ9Vδ2
    Murday AS; Chaudhry S; Pauza CD
    Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet.
    Aehnlich P; Carnaz Simões AM; Skadborg SK; Holmen Olofsson G; Thor Straten P
    Front Immunol; 2020; 11():1868. PubMed ID: 32983105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
    Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
    Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vγ9Vδ2 T cells expressing a BCMA-Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth.
    Zhang X; Ng YY; Du Z; Li Z; Chen C; Xiao L; Chng WJ; Wang S
    PLoS One; 2022; 17(6):e0267475. PubMed ID: 35709135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
    Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
    J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy.
    Ridgley LA; Caron J; Dalgleish A; Bodman-Smith M
    Front Immunol; 2022; 13():1065495. PubMed ID: 36713444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.
    Correia DV; d'Orey F; Cardoso BA; Lança T; Grosso AR; deBarros A; Martins LR; Barata JT; Silva-Santos B
    PLoS One; 2009 May; 4(5):e5657. PubMed ID: 19479075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.